We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
The epidemiology, symptoms, diagnosis and management of human T-cell lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2).
The NHSBT and UKHSA surveillance programme is a series of national schemes that monitors infection in blood, tissue and organ donors, and transfusion recipients.
This template is used to notify GPs of a suspected positive newborn blood spot screening result of congenital hypothyroidism (CHT).
Topical steroid products are safe and highly effective treatments for the management of a wide range of inflammatory skin diseases but have important risks, especially with prolonged use at high potency. In the coming months, as a result of regulatory...
Information and service documents on the national DBS testing service offered by PHE to improve uptake of 12 month testing of infants born to hepatitis B infected mothers.
Information for parents about congenital hypothyroidism (CHT) following a baby’s screening test result.
Information about ensuring blood and blood component safety.
Guidelines for laboratories screening newborns for congenital hypothyroidism (CHT) in the UK.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
This guidance (HPA-CRCE-044) gives a procedure for monitoring of the thyroid using mini instruments type 44 and type 42 probes.
The NHSBT / PHE epidemiology unit, and the epidemiology of infections among blood, tissue and organ donors and recipients.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).